Caterina Marchi

List of Publications by Citations

148 papers	5,208 citations	39 h-index	68 g-index
162 ext. papers	6,182 ext. citations	6.8 avg, IF	5.27 L-index

#	Paper	IF	Citations
148	FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. *Cancer Research*, **2010**, 70, 2085-94	10.1	533
147	Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. *Breast Cancer Research and Treatment*, **2008**, 111, 27-44	4.4	257
146	Breast cancer precursors revisited: molecular features and progression pathways. *Histopathology*, **2010**, 57, 171-92	7.3	232
145	Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. *Journal of Pathology*, **2009**, 219, 16-24	9.4	164
144	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. *Nature Genetics*, **2014**, 46, 1166-9	36.3	150
143	Tiling path genomic profiling of grade 3 invasive ductal breast cancers. *Clinical Cancer Research*, **2009**, 15, 2711-22	12.9	138
142	ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. *Annals of Oncology*, **2019**, 30, 1417-1427	10.3	133
141	PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. *Clinical Cancer Research*, **2009**, 15, 2269-80	12.9	128
140	SF3B1 mutations constitute a novel therapeutic target in breast cancer. *Journal of Pathology*, **2015**, 235, 571-80	9.4	124
139	Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. *Laboratory Investigation*, **2008**, 88, 491-503	5.9	116
138	Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. *Journal of Pathology*, **2008**, 215, 398-410	9.4	116
137	Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. *Journal of Pathology*, **2012** , 227, 42-52	9.4	115
136	Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas). *Journal of Clinical Pathology*, **2010**, 63, 220-8	3.9	109
135	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. *Npj Breast Cancer*, **2016**, 2, 16036	7.8	89
134	Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. *Seminars in Diagnostic Pathology*, **2010**, 27, 69-76	4.3	88
133	Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. *Journal of Clinical Pathology*, **2008**, 61, 327-32	3.9	87
132	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression. *Journal of Pathology*, **2016**, 238, 508-18	9.4	80

131	Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. *Journal of Pathology*, **2014**, 232, 553-65	9.4	75
130	Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. *Histopathology*, **2012**, 61, 629-43	7.3	75
129	Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?. *Genes Chromosomes and Cancer*, **2009**, 48, 351-65	5	74
128	Classification of pulmonary neuroendocrine tumors: new insights. *Translational Lung Cancer Research*, **2017**, 6, 513-529	4.4	72
127	Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes. *Histopathology*, **2008**, 52, 840-6	7.3	69
126	The genomic profile of HER2-amplified breast cancers: the influence of ER status. *Journal of Pathology*, **2008**, 216, 399-407	9.4	69
125	MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast. *Histopathology*, **2015**, 67, 719-29	7.3	68
124	ESR1 gene amplification in breast cancer: a common phenomenon?. *Nature Genetics*, **2008**, 40, 809-10; author reply 810-2	36.3	66
123	Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2006**, 449, 288-96	5.1	66
122	Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. *Journal of Pathology*, **2009**, 218, 301-15	9.4	65
121	Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. *Endocrine-Related Cancer*, **2011**, 18, 565-77	5.7	64
120	Pleomorphism of the nuclear envelope in breast cancer: a new approach to an old problem. *Journal of Cellular and Molecular Medicine*, **2008**, 12, 209-18	5.6	54
119	Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues. *Frontiers in Oncology*, **2013**, 3, 129	5.3	51
118	Nestin is expressed in basal-like and triple negative breast cancers. *Journal of Clinical Pathology*, **2008**, 61, 1045-50	3.9	51
117	Distinctive pathological and clinical features of lung carcinoids with high proliferation index. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2017**, 471, 713-720	5.1	48
116	CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. *Breast Cancer Research and Treatment*, **2010**, 120, 95-109	4.4	47
115	Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine. *Pathobiology*, **2018**, 85, 23-34	3.6	45
114	Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2 Scaffolding Function. *Cancer Cell*, **2017**, 32, 444-459.e7	24.3	44

113	Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. *Histopathology*, **2012**, 60, E115-30	7.3	42
112	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. *Journal of Pathology*, **2015**, 237, 166-78	9.4	42
111	The role of molecular analysis in breast cancer. *Pathology*, **2009**, 41, 77-88	1.6	41
110	The Genomic Landscape of Mucinous Breast Cancer. *Journal of the National Cancer Institute*, **2019**, 111, 737-741	9.7	41
109	The genetic landscape of breast carcinomas with neuroendocrine differentiation. *Journal of Pathology*, **2017**, 241, 405-419	9.4	35
108	Hereditary breast cancer: from molecular pathology to tailored therapies. *Journal of Clinical Pathology*, **2008**, 61, 1073-82	3.9	35
107	Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. *Seminars in Cancer Biology*, **2021**, 72, 123-135	12.7	35
106	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. *Modern Pathology* , **2017**, 30, 69-84	9.8	34
105	BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. *Clinical Cancer Research*, **2016**, 22, 4923-4933	12.9	34
104	Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box. *BMC Medicine*, **2011**, 9, 41	11.4	33
103	Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast. *Human Pathology*, **2015**, 46, 1350-9	3.7	32
102	Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. *Modern Pathology*, **2018**, 31, 68-82	9.8	32
101	Molecular alterations of neuroendocrine tumours of the lung. *Histopathology*, **2018**, 72, 142-152	7.3	32
100	Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors. *Drug Delivery*, **2017**, 24, 670-680	7	31
99	Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis. *Molecular Cytogenetics*, **2014**, 7, 8	2	31
98	Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method. *Oncologist*, **2014**, 19, 1118-26	5.7	30
97	miR-221/222 control luminal breast cancer tumor progression by regulating different targets. *Cell Cycle*, **2014**, 13, 1811-26	4.7	30
96	The expression of Wilms' tumour-1 and Ca125 in invasive micropapillary carcinoma of the breast. *Histopathology*, **2007**, 51, 824-8	7.3	30

95	The pathologic complete response open question in primary therapy. *Journal of the National Cancer Institute Monographs*, **2011**, 2011, 86-90	4.8	28
94	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits. *Cancer Research*, **2019**, 79, 5884-5896	10.1	26
93	High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast. *Histopathology*, **2018**, 73, 273-283	7.3	25
92	Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues. *Laboratory Investigation*, **2015**, 95, 561-71	5.9	24
91	Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. *Breast Cancer Research and Treatment*, **2014**, 148, 511-23	4.4	23
90	Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. *Npj Breast Cancer*, **2016**, 2, 16035	7.8	23
89	Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies. *Oncogene*, **2014**, 33, 619-31	9.2	21
88	A collection of primary tissue cultures of tumors from vacuum packed and cooled surgical specimens: a feasibility study. *PLoS ONE*, **2013**, 8, e75193	3.7	21
87	The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas. *Pathobiology*, **2020**, 87, 125-142	3.8	21
86	Tissue arrays as fiducial markers for section alignment in 3-D reconstruction technology. *Journal of Cellular and Molecular Medicine*, **2005**, 9, 438-45	5.6	20
85	Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers. *Cell Death and Differentiation*, **2019**, 26, 2223-2236	12.7	19
84	Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study. *Modern Pathology*, **2010**, 23, 260-9	9.8	19
83	PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid. *Modern Pathology*, **2019**, 32, 1734-1743	9.8	18
82	A new vision of tubular and tubulo-lobular carcinomas of the breast, as revealed by 3-D modelling. *Histopathology*, **2006**, 48, 556-62	7.3	18
81	Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. *Frontiers in Oncology*, **2021**, 11, 644737	5.3	18
80	ESR1 amplification in endometrial carcinomas: hope or hyperbole?. *Journal of Pathology*, **2008**, 216, 271-4	5.4	17
79	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. *Modern Pathology*, **2020**, 33, 354-366	9.8	17
78	Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. *Journal of Pathology*, **2013**, 229, 390-9	9.4	16

77	"To be or not to be in a good shape": diagnostic and clinical value of nuclear shape irregularities in thyroid and breast cancer. *Advances in Experimental Medicine and Biology*, **2014**, 773, 101-21	3.6	16
76	Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization. *Oncotarget*, **2017**, 8, 18680-18698	3.3	15
75	Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells. *BMC Cancer*, **2014**, 14, 922	4.8	15
74	mutations in metastatic lobular breast cancer patients. *Npj Breast Cancer*, **2019**, 5, 9	7.8	15
73	RollFISH achieves robust quantification of single-molecule RNA biomarkers in paraffin-embedded tumor tissue samples. *Communications Biology*, **2018**, 1, 209	6.7	15
72	PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. *Gynecologic Oncology*, **2015**, 137, 321-8	4.9	14
71	Acid-free glyoxal as a substitute of formalin for structural and molecular preservation in tissue samples. *PLoS ONE*, **2017**, 12, e0182965	3.7	14
70	High-throughput molecular analysis from leftover of fine needle aspiration cytology of mammographically detected breast cancer. *Translational Oncology*, **2012**, 5, 180-9	4.9	14
69	The Perfect Pathology Report After Neoadjuvant Therapy. *Journal of the National Cancer Institute Monographs*, **2015**, 2015, 47-50	4.8	12
68	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. *Journal of Experimental and Clinical Cancer Research*, **2020**, 39, 279	12.8	12
67	AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells. *Cells*, **2020**, 9,	7.9	12
66	The expression of LINE1-MET chimeric transcript identifies a subgroup of aggressive breast cancers. *International Journal of Cancer*, **2018**, 143, 2838-2848	7.5	11
65	Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM). *Cancers*, **2019**, 11,	6.6	11
64	Search for neuro-endocrine markers (chromogranin A, synaptophysin and VGF) in breast cancers. An integrated approach using immunohistochemistry and gene expression profiling. *Endocrine Pathology*, **2014**, 25, 219-28	4.2	11
63	Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. *Neuro-Oncology*, **2017**, 19, 451-453	1	10
62	Predictive Diagnostic Pathology in the Target Therapy Era in Breast Cancer. *Current Drug Targets*, **2017**, 18, 4-12	3	10
61	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. *Clinical Cancer Research*, **2020**, 26, 6254-6265	12.9	10
60	The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment. *American Journal of Surgical Pathology*, **2018**, 42, 1190-1200	6.7	10

59	Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications. *Current Breast Cancer Reports*, **2017**, 9, 34-44	0.8	9
58	Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. *Annals of Oncology*, **2007**, 18, 1963-8	10.3	9
57	CUTseq is a versatile method for preparing multiplexed DNA sequencing libraries from low-input samples. *Nature Communications*, **2019**, 10, 4732	17.4	8
56	Molecular diagnosis in breast cancer. *Diagnostic Histopathology*, **2008**, 14, 202-213	0.7	8
55	Myxoid renal tumor with myoepithelial differentiation mimicking a salivary gland pleomorphic adenoma: description of a case. *American Journal of Surgical Pathology*, **2007**, 31, 632-6	6.7	8
54	Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors. *Cancers*, **2021**, 13,	6.6	8
53	Basic principles of biobanking: from biological samples to precision medicine for patients. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 479, 233-246	5.1	8
52	Caveolin 1 expression favors tumor growth and is associated with poor survival in primary lung adenocarcinomas. *Tumor Biology*, **2017**, 39, 1010428317694311	2.9	7
51	The expression of GHRH and its receptors in breast carcinomas with apocrine differentiation-further evidence of the presence of a GHRH pathway in these tumors. *Human Pathology*, **2017**, 64, 164-170	3.7	7
50	Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene. *British Journal of Cancer*, **2017**, 117, 358-366	8.7	7
49	Chemotherapy with or without trastuzumab. *Annals of Oncology*, **2010**, 21 Suppl 7, vii112-9	10.3	7
48	Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast. *Molecular Oncology*, **2017**, 11, 913-926	7.9	6
47	Tissues under-vacuum to overcome suboptimal preservation. *New Biotechnology*, **2019**, 52, 104-109	6.4	6
46	Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study. *Histopathology*, **2019**, 75, 312-319	7.3	6
45	Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression. *American Journal of Pathology*, **2018**, 188, 2378-2391	5.8	6
44	Rediscovering Secondary Tumors of the Prostate in the Molecular Era. *Advances in Anatomic Pathology*, **2016**, 23, 170-9	5.1	6
43	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. *Molecular Oncology*, **2021**, 15, 1024-1039	7.9	6
42	Optimized EGFR Blockade Strategies in Addicted Gastroesophageal Adenocarcinomas. *Clinical Cancer Research*, **2021**, 27, 3126-3140	12.9	6

41	Cold Formalin Fixation Guarantees DNA Integrity in Formalin Fixed Paraffin Embedded Tissues: Premises for a Better Quality of Diagnostic and Experimental Pathology With a Specific Impact on Breast Cancer. *Frontiers in Oncology*, **2020**, 10, 173	5.3	5
40	Small-cell carcinoma of the breast with squamous differentiation. *Histopathology*, **2013**, 63, 739-41	7.3	5
39	Traditional urinary cytology and tyrosinase RT-PCR in metastatic melanoma patients: correlation with clinical status. *Journal of Clinical Pathology*, **2008**, 61, 179-83	3.9	5
38	Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes. *Endocrine-Related Cancer*, **2016**, 23, 635-50	5.7	5
37	Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network. *Pathologica*, **2021**, 113, 262-271	1.9	5
36	Unusual Patterns of HER2 Expression in Breast Cancer: Insights and Perspectives.. *Pathobiology*, **2022**, 1-19	3.6	5
35	Oncogenic properties and signaling basis of the PAX8-GLIS3 fusion gene. *International Journal of Cancer*, **2020**, 147, 2253-2264	7.5	4
34	RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers. *European Journal of Cancer*, **2016**, 64, 149-58	7.5	4
33	Well-differentiated neuroendocrine tumour of the breast showing peculiar endovascular spread. *Histopathology*, **2014**, 64, 597-600	7.3	4
32	Incorporation of TILs in daily breast cancer care: how much evidence can we bear?. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2022**, 1	5.1	4
31	The impact of malignant nipple discharge cytology (NDc) in surgical management of breast cancer patients. *PLoS ONE*, **2017**, 12, e0182073	3.7	4
30	Reoperation rate after breast conserving surgery as quality indicator in breast cancer treatment: A reappraisal. *Breast*, **2020**, 53, 181-188	3.6	4
29	Assessment of a High Sensitivity Method for Identification of R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients. *Cancers*, **2019**, 11,	6.6	3
28	Molecular diagnosis in breast cancer. *Diagnostic Histopathology*, **2018**, 24, 71-82	0.7	3
27	Awareness of mutational artefacts in suboptimal DNA samples: possible risk for therapeutic choices. *Expert Review of Molecular Diagnostics*, **2018**, 18, 467-475	3.8	3
26	Current projects in Pre-analytics: where to go?. *Recent Results in Cancer Research*, **2015**, 199, 65-70	1.5	3
25	Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer. *Cancers*, **2021**, 13,	6.6	3
24	Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. *Breast*, **2021**, 59, 94-101	3.6	3

23	Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma. *Histopathology*, **2017**, 71, 480-487	7.3	2
22	"Giants in a Microcosm": Multinucleated Giant Cells Populating an Invasive Micropapillary Carcinoma of the Breast. *International Journal of Surgical Pathology*, **2015**, 23, 654-5	1.2	2
21	Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio 2.0, HER2 copy number . *British Journal of Cancer*, **2021**, 124, 1836-1842	8.7	2
20	Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer. *Cancers*, **2021**, 13,	6.6	2
19	CXCL12 expression is a bona fide predictor of recurrence in lung neuroendocrine tumours; a multicentric study with emphasis on atypical carcinoids a short report. *Cellular Oncology (Dordrecht)*, **2018**, 41, 687-691	7.2	2
18	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. *Modern Pathology*, **2021**, 34, 2130-2140	9.8	2
17	Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites. *Journal of Clinical Pathology*, **2020**,	3.9	1
16	Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification. *Journal of Experimental and Clinical Cancer Research*, **2017**, 36, 143	12.8	1
15	Next-generation learning and training: The Cy-TEST experience. *Cancer Cytopathology*, **2017**, 125, 669-673	3.9	1
14	The Immune Landscape in Women Cancers. *Cancer Treatment and Research*, **2020**, 180, 215-249	3.5	1
13	Breast Pathology. *Encyclopedia of Pathology*, **2020**, 289-293	0	1
12	Personalized therapeutic strategies in HER2-driven gastric cancer. *Gastric Cancer*, **2021**, 24, 897-912	7.6	1
11	Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients. *Cancers*, **2021**, 13,	6.6	1
10	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. *ESMO Open*, **2022**, 7, 100459	6	1
9	Pathology and Molecular Pathology of Breast Cancer **2017**, 173-231		0
8	"Borderline" epithelial lesions of the breast: what have we learned in the past three decades?. *Pathologica*, **2021**, 113, 354-359	1.9	0
7	HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast. *Journal of Hematology and Oncology*, **2021**, 14, 143	22.4	0
6	Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors.. *Npj Precision Oncology*, **2022**, 6, 15	9.8	0

5	Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer. *JAMA Oncology*, **2020**, 6, 584-585	13.4
4	Evoluzione dell'istopatologia: da flatlandia a una visione a tre dimensioni **2007**, 255-261	
3	Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification. *American Journal of Cancer Research*, **2015**, 5, 2212-21	4.4
2	Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast.. *Journal of Clinical Oncology*, **2020**, 38, e12570-e12570	2.2
1	HER2 in Breast Cancer. *Encyclopedia of Pathology*, **2020**, 151-161	0